Fri, Sep 13, 2024
Volume 10, Issue 4 (12-2022)
J. Pediatr. Rev 2022, 10(4): 273-276 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghaffari J. Biologic Drugs Treatment of Chronic Urticaria. J. Pediatr. Rev 2022; 10 (4) :273-276
URL: http://jpr.mazums.ac.ir/article-1-499-en.html
URL: http://jpr.mazums.ac.ir/article-1-499-en.html
Department of Paediatrics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. , javadneg@yahoo.com
Abstract: (1645 Views)
Chronic Urticaria (CU) is a skin disorder characterized by wheal and flare with a duration of more than 6 weeks affecting 1%-2% of the population (more common in women). Thirty to 35% of cases of CU have angioedema [1]. The etiology of chronic spontaneous urticarial is not usually clear, 40%-50% are idiopathic and 30%-40% are autoimmune [2, 3]. Quality of life in CU is usually disturbed which has a direct relation with severity [4].
Type of Study: Letter to the Editor |
Subject:
Allergy and Clinical Immunology
Received: 2022/10/9 | Accepted: 2022/10/12 | Published: 2022/12/19
Received: 2022/10/9 | Accepted: 2022/10/12 | Published: 2022/12/19
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC),
which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
